A live audio webcast of Idera’s presentation will be accessible in the Investors and Media section of Idera’s website at http://www.iderapharma.com. An archived version will also be available on the company’s website after the event for 90 days.
Harnessing the approach of the earliest researchers in immunotherapy and the Company’s vast experience in developing proprietary immunology platforms, Idera’s lead development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy.
IDERA PHARMACEUTICALS Contact:
SVP, Investor Relations
Phone (484) 348-1677
Source: Idera Pharmaceuticals, Inc.